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Abstract
Prescription drug cost sharing is an effective tool to reduce the excessive drug consumption. However,
many times it could have a negative impact on the drug utilization especially in case of chronic
conditions. Chronic conditions such as asthma require appropriate utilization of controller medication to
keep the inflammation and symptoms under control. Literature on asthma drug utilization has
consistently reported underuse of controller drugs among asthma patients. The present study attempted
to investigate the impact of prescription drug cost sharing levels on the controller adherence among the
privately insured asthma population with moderate persistent asthma. The study also analyzed the
relationship between adherence and asthma related health services utilization outcomes.
A retrospective analysis using the MarketScan administrative claims database was conducted for the
years 2000 and 2001. Asthma patients that were stepped up to dual controller therapy in the study period
and had no diagnosis for COPD or other respiratory conditions were included in the study. Study
participants were also required to be in the age range of 5-65 and continuously enrolled in the health plan
for the entire study period. Multivariate regression analysis using SAS 9.1 was performed to analyze the
relationship between cost sharing levels and controller adherence. Linear probabilistic models were built
to analyze the relationship between adherence and asthma related health services utilization.
A total of 1447 patients met the study criteria. The overall association between cost sharing and
adherence was significantly negative. The drop in adherence to Inhaled Corticosteroids (ICS) with respect
to cost sharing was greater after the patients were stepped to the dual controller therapy. Comparison of
subgroups that used ICS+ LABA and ICS + LTRA revealed that the subjects ICS+LTRA subgroup are
slightly more sensitive to the out of pocket costs. The analysis of adherence and health services
utilization showed mixed results with reduction in ER visits but no association of hospital stay and SAB
use.
Cost sharing levels had a negative impact on utilization of controller drugs. In terms of ICS adherence pre
and post index periods, it can be concluded that the increased cost burden affected significantly even
though the need to be adherent was increased. Based on the sub group analysis in the post-index period
between the two add-on options, ICS + LTRA subgroup was more sensitive to the price changes.
Adherence to controller regimen had a negative impact on ER visits however the data did not provide
evidence in case of hospitalizations and SAB use.
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Abstract

Prescription drug cost sharing is an effective tool to reduce the excessive drug
consumption. However, many times it could have a negative impact on the drug
utilization especially in case of chronic conditions. Chronic conditions such as asthma
require appropriate utilization of controller medication to keep the inflammation and
symptoms under control. Literature on asthma drug utilization has consistently reported
underuse of controller drugs among asthma patients. The present study attempted to
investigate the impact of prescription drug cost sharing levels on the controller adherence
among the privately insured asthma population with moderate persistent asthma. The
study also analyzed the relationship between adherence and asthma related health
services utilization outcomes.
A retrospective analysis using the MarketScan administrative claims database was
conducted for the years 2000 and 2001. Asthma patients that were stepped up to dual
controller therapy in the study period and had no diagnosis for COPD or other respiratory
conditions were included in the study. Study participants were also required to be in the
age range of 5-65 and continuously enrolled in the health plan for the entire study period.
Multivariate regression analysis using SAS 9.1 was performed to analyze the relationship
between cost sharing levels and controller adherence. Linear probabilistic models were
built to analyze the relationship between adherence and asthma related health services
utilization.
A total of 1447 patients met the study criteria. The overall association between
cost sharing and adherence was significantly negative. The drop in adherence to Inhaled
Corticosteroids (ICS) with respect to cost sharing was greater after the patients were
stepped to the dual controller therapy. Comparison of subgroups that used ICS+ LABA
and ICS + LTRA revealed that the subjects ICS+LTRA subgroup are slightly more
sensitive to the out of pocket costs. The analysis of adherence and health services
utilization showed mixed results with reduction in ER visits but no association of hospital
stay and SAB use.
Cost sharing levels had a negative impact on utilization of controller drugs. In
terms of ICS adherence pre and post index periods, it can be concluded that the increased
cost burden affected significantly even though the need to be adherent was increased.
Based on the sub group analysis in the post-index period between the two add-on options,
ICS + LTRA subgroup was more sensitive to the price changes. Adherence to controller
regimen had a negative impact on ER visits however the data did not provide evidence in
case of hospitalizations and SAB use.
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Chapter I: Introduction
1.1 Overview
The concept of cost sharing in healthcare has been around for years. Work
published by health economist Kenneth Arrow demonstrated the phenomenon of moral
hazard among those with health insurance,1 which in turn stimulated a need to contain the
moral hazard. Moral hazard is defined as the change in behavior when people are
insulated from risk.2 It happens when an individual does not carry the responsibility of
their actions, has a tendency to act less carefully than he/she otherwise would. In a
response to counter the moral hazard, insurance companies started using several cost
sharing techniques such as annual deductibles and co-payments to control the overall
healthcare expenditures. The success of cost sharing techniques in controlling the moral
hazard is well documented by previous studies.3-5 However, while the cost sharing
strategy is observed as an excellent tool to counter the moral hazard and unnecessary
drug utilization, it has also been documented that the higher cost sharing levels may lead
to under use of heath care.6 Hence to maintain an optimum balance between cost sharing
and appropriate health care consumption, it is important to study the effect of cost sharing
on patient adherence to the treatment.
Even though prescription drugs are part of health care services, in a typical health
insurance coverage policy they are separated from other health services and form a
supplementary addition to a health coverage policy. However, as the prices for
prescription drugs started rising, insurance companies have introduced cost sharing
policies in the supplementary drug policies as well. The main purpose of cost sharing
again was to discourage patients from consuming unnecessary care. On the other hand if
the patients have to pay too much out of pocket cost they may be discouraged from
utilizing necessary care. Therefore achieving the correct balance where patients are
encouraged to use needed care but at the same time are discouraged to use unneeded care
is critical. This brings us to an important issue where we need to determine if cost sharing
levels imposed in the drug plans are adversely affecting utilization of necessary drugs
especially in cases of chronic conditions where poor adherence may lead to worse
outcomes.
In this study, the investigator sought to determine the impact of cost sharing on
adherence to asthma controller drugs among asthma patients from age five and above.
The focus was on the patients with asthma severity at a moderate persistent level which is
characterized by use of more than one controller medication. In case of moderate
persistent asthma, the patients need more medical attention as their asthma is not
controlled by one controller medication alone. Poor adherence to the controller
1

medication has more severe implications in case of these asthma patients. Therefore
compared to the asthma patients with mild asthma these patients are in greater need of
being adherent to the prescribed regimen for asthma treatment.

1.2 Background
Asthma is a chronic respiratory condition and if not managed effectively it may
result in hospitalizations, emergency room visits, and reduced quality of life.7 Besides
avoiding the things that trigger an asthma attack, the most effective treatment for asthma
is use of medications.8 There are mainly two types of medications available for asthma
treatment, short acting relievers and long acting controllers. The current National Heart,
Lung, and Blood Institute (NHLBI) guidelines8 for the treatment of persistent asthma
advocate use of long-term control medications (to be taken daily on a long-term basis) to
achieve and maintain adequate control. For asthma patients suffering from daily
symptoms and requiring use of Short Acting Bronchodilators (SAB) on an everyday basis
along with exacerbations affecting activity greater than two times per week, guidelines
recommend use of dual controller therapy.9 Dual controller therapy is a combination of
Inhaled Corticosteroids (ICS) along with another controller drug such as Long-acting
inhaled 2-agonist (LABA) or Leukotrine Receptor Antagonist (LTRA).

1.2.1 Poor adherence to controller drugs
Despite the recommendations from national asthma guidelines, the controller drug
underutilization and overuse of the quick relief medications still persists.10-12 The
Epidemiology and Natural History of Asthma Outcomes and Treatment Regimens
(TENOR) study reported that the controller drug utilization is less than optimum among
many asthma patients who are at high risk of morbidity and mortality.11 The asthma
medication treatment emphasis is shifting towards more use of the controller drugs that
are effective in preventing asthma exacerbations than the relievers that play no role in
controlling the asthma itself. Poor adherence to the controller drugs is also considered a
major contributor towards poor control and morbidity associated with asthma. If asthma
is not controlled adequately then it can affect the severity levels of the disease resulting in
more severe asthma condition.
For asthma patients having moderate persistent or higher severity, NHLBI
guidelines9 emphasize even greater focus on use of controller drugs. Patients are
recommended to initiate a step up therapy consisting of two different controller drugs.
However, studies have reported lower rate of adherence even among these patients that
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needs more attention. Stern et al reported an average MPR (Medication Possession Ratio)
of 0.36 among the asthma population taking more than one controller medication.12
Considering that the value for MPR ranges from 0 to 1, 0.36 indicates a very low
adherence. Unfortunately there is no cure for asthma and the only means to treat asthma
besides avoiding the substances that trigger asthma attacks is to use medications. Poor
adherence to controller medications even among asthma patients that are in more need to
control their conditions, highlights the need to investigate factors behind the low
adherence and possible solutions to improve the adherence.

1.2.2 Relationship between out of pocket cost and adherence
As mentioned earlier out of pocket cost has an inverse relationship with adherence
to the medications across a wide range of chronic conditions. Several studies6,13-15 have
documented significant rates of medication underuse as a result of the burden of out of
pocket costs in the United States. In the case of chronic conditions such as asthma,
medication adherence is essential to control the disease. However, if out of pocket costs
are unaffordable to the patients, then it is likely that they will skip the medication.
Moreover, majority of the controller drugs (such as widely used ICS) do not produce any
symptomatic relief making them more vulnerable to poor adherence rates. A study done
by Byer et al16 using Leventhal‟s Self Regulatory Model (SRM) as a theoretical
framework found that the symptoms associated with the illness play a key role in
adherence to then medication among asthma patients. Medications such as asthma
controllers have to be taken for a very long time without being able to experience
immediate symptomatic relief and therefore higher costs associated with such
medications can discourage the patients from utilizing the drugs properly.
As mentioned before, lower adherence to controller drugs can lead to worsening
the asthma symptoms which ultimately can result in a stepped up therapy with dual
controller medications.17 According to national guidelines patients are stepped up from
one controller medication to two medications when asthma is not controlled enough by
one controller alone.9 To achieve better control over the condition, patients need more
than one controller drugs. Severity indicators such as inflammation levels and lung
function are worse among such patients and therefore they are required to be more
adherent to the treatment regimen than the patients having their asthma severity at mild
level.
Once the patients are stepped up to the dual controller therapy they have to pay
for two controller drugs making the overall treatment less affordable and more
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burdensome. Compared to the reliever drugs, controller drugs are more expensive and
when searched for the various drug plans offered in Tennessee were found to be placed in
the second or third tier of the pharmacy benefit plan. According to drugstore.com (an
online retailer of prescription drugs), the cost of Azmacort (asthma controller drug)
inhaler was found to be $131.24 whereas Alupent (Short Acting Bronchodilator) 0.65mg/act Aerosol 14gm Inhaler was found to be for $37.87.

1.3 Conceptual Framework
As improved outcomes are expected through appropriate adherence to them, first
it is necessary to establish a relationship between the health insurance status and asthma
drug utilization, before analyzing the economical and health outcomes. However the
individual healthcare utilization cannot be explained as a function of coinsurance level
alone. It is characterized by a person‟s individual and social determinants. In order to
measure the isolated effects of health insurance status on the drug utilization, it is
necessary to identify and control for all the individual and social characteristics that are
likely to influence one‟s health care utilization. To control the factors influencing one‟s
prescription drug utilization, the conceptual framework of this study incorporated the
health utilization model developed by R.M Anderson15
This model has been cited by several studies18-20 focusing on health services
utilization among asthma patients. Initially this model was developed to focus on „family‟
as the unit of analysis. Later on it was modified to shift the focus to the „individual‟ as the
unit of analysis to address the health services utilization more appropriately.21 This model
captures health services utilization behavior as a function of their 1) predisposition to use;
2) enabling resources to use; and 3) need to use the health services.

1.3.1 Predisposing characteristics
Every individual has a different propensity to use health care resources.21
Existence of different propensities is a result of the diversity in characteristics of every
individual. Such characteristics are broadly categorized into demographic, social
structural and attitudinal-belief variables under the predisposing factors to use the health
care services. Demographics such as age and sex are examples of demographic variables
that are closely related to health of an individual. The social structure variables refer to
the status of the individual in his society. Depending upon these characteristics use of
health care services varies among different patient populations. Although predisposing
variables are not directly associated with the patient‟s healthcare utilization patterns, they
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create differences in inclinations towards use of health care services. As a result, the
different healthcare utilization patterns are observed with different predisposing
characteristics. For example, people in different age groups have different types of
illnesses and severities and therefore are likely to have different healthcare use patterns.
In case of asthma predisposing factor such as age is important because the evidence
indicates that aging has an adverse effect on lung elastin fibers which has been correlated
to the severity of the disease.22

1.3.2 Enabling resources
Being predisposed to utilization alone may not result in actual utilization of the
health services. Along with predisposition to use, adequate resources are required to be
available to translate the predisposition into actual use. There are two major categories of
enabling resources, personal/ family and community. Family/personal income is an
example of variable in personal/family category affecting individual utilization of health
services. Variables such as, availability of health care facilities and access to them fall
under the community category of enabling resources. Other community variables such as
rural or urban nature of the community also influence use of health services because they
sometimes are associated with the way how the medicine should be practices. Enabling
resources play a key role by providing necessary means to obtain the health care services
by the patients.

1.3.3 Need
Other than the predisposition to use and availability of enabling resources,
presence of an illness and degree of it is also important in predicting health services use.
It is important for an individual or a family to perceive the illness or probability of its
occurrence to seek any kind of health care services. Being predisposed and availability of
necessary means are not sufficient to use healthcare services if there is no need for it
perceived by the individual or the family. Need characteristics explain the behavior of
those patients who are predisposed to the health care use and also have means to obtain it
but are still not consuming it. Illness level represents the most immediate cause to use any
health services. Examples of perceived illness include self reported general state of health
such as excellent, good, poor etc.
The final conceptual framework for this study (Figure 1) was created by
extending the Anderson‟s health utilization model further to include the asthma related
healthcare resources utilization outcomes.
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Figure 1 Conceptual framework based on Anderson‟s healthcare utilization model
Source: Modified with permission Andersen RM. Revisiting the behavioral model and
access to medical care: does it matter? J Health Soc Behav 1995 March;36(1):1-10.18
Legend: ER = Emergency Room.
SAB = Short Acting Bronchodilators.
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Once the link between cost sharing and medication utilization is established it is
important to analyze effects of adherence levels on healthcare resources utilization
outcomes to fully understand the impact of cost related poor adherence. Cost related poor
adherence has been documented to be associated with poor health outcomes in case of
chronic conditions.23 Extending the Anderson‟s model to include healthcare services
utilization outcomes, helped to understand if patients who are struggling to be adherent to
the controller regimen are suffering from poor healthcare resources utilization outcomes
as well. Healthcare services utilization outcomes associated with asthma such as ER visit,
hospitalization and use of SAB were included. This conceptual framework helped us to
determine the variables to be measured and also the statistical relationships required to be
studied.

1.4 Objectives and Specific Aims

1.4.1 Objectives
The main objectives of this study were to examine the impact of cost sharing
among asthma population suffering from moderate persistent asthma (age group 4-65) on
adherence to asthma controller medications and also to analyze patient level outcomes
such as ER visits, hospitalization and use of SAB. The study had the following specific
aims:

1.4.2 Specific aims and hypotheses
1. To determine the distribution of asthmatic population diagnosed with
moderate persistent asthma (stepped up from Inhaled corticosteroids alone to
Inhaled Corticosteroids + Long-acting inhaled 2-agonist (ICS+LABA) and
Inhaled Corticosteroids + Leukotrine Receptor Antagonist (ICS + LTRA))
2. To quantify the change in Medication Possession Ratio (adherence measure)
of controller medication combination (ICS+LABA/LTRA) with respect to
increase in cost sharing level after controlling for other covariates.
Hypothesis: As the increased cost sharing levels are known to have inverse
relationship with the utilization of health care services, it is hypothesized that
the MPR for the asthma patients will go down as the cost sharing levels go up.
The null and alternative hypotheses are,
H0: MPR does not change with change in cost sharing levels

7

H1: MPR changes with change in cost sharing levels
2a. To compare changes in Medication Possession Ratio (adherence
measure) with respect to increase in cost sharing level between
patients stepped up with ICS+LABA and patients stepped up with
ICS+LTRA combination
Hypothesis: As the LABA and LTRA have different mechanism of
actions it is hypothesized that adherence levels will be with respect to
the cost sharing levels will be significantly different. The null and
alternative hypotheses are,
H0: There is no change in MPR with respect to cost sharing levels
among ICS+LABA and ICS+LTRA users.
H1: The MPR with respect to cost sharing levels changes among
ICS+LABA and ICS+LTRA users.
2b. To analyze change in medication possession ratio with respect to
increase in cost sharing levels of ICS only before and after the
patients were stepped up to the dual controller therapy.
Hypothesis: As the increased cost sharing levels are known to have
inverse relationship with the utilization of health care services, it is
hypothesized that the MPR for the asthma patients will go down as
the cost sharing levels go up. The null and alternative hypotheses are,
H0: There is no change in ICS MPR with respect to cost sharing
levels before and after getting steeped up to dual controller therapy.
H1: The ICS MPR with respect to cost sharing levels changes before
and after getting stepped up to dual controller therapy.
3.

To examine the association between adherence to asthma controller therapy
and asthma related health services utilization (SAB utilization, ER visits,
Hospitalization) among the moderate persistent asthma patients.
Hypothesis: The controller therapy has been reported to be effective for the
asthma patients in controlling the conditions and therefore it is hypothesized
that the adherence levels will result in decreasing the asthma related health
services utilization such as SAB use, ER visits, Hospitalization. The null and
alternative hypotheses are,
H0: Adherence to controller drugs has no impact on asthma related health
services utilization.
H1: Adherence to controller drugs has a negative impact on asthma related
health services utilization.
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1.5 Significance
The prevalence of asthma along with the severity and frequency of exacerbations
appears to be increasing worldwide.24 In addition the lower rates of controller adherence
are contributing to worsening the situation. Despite the recommendations from guidelines
to use more than one controller drug, the studies have reported lower levels of controller
adherence even among asthma patients having moderate persistent asthma. So far the
factors reported in the literature to be associated with lower adherence to controller
medications are lack of medication efficacy (real or perceived), taste of medication,
multiple dosing intervals, long stressful demanding regimens and incorrect prescription
given by clinicians.12
At the same time to control the increase in prescription drug spending many plans
are increasing the levels of copayment across all tiers leading to an increased cost burden
on patients.25 This increase in copayment level brings up two important issues needed to
be addressed: 1) Does the increase in cost sharing level affect the utilization of
appropriate prescription drugs; and 2) To what degree the health outcomes associated
with the utilization are affected. There is a significant body of research showing the
association of higher cost sharing and lower adherence levels, but impact of cost sharing
on adherence in case of asthma patients has not been explored thoroughly with only a few
studies available. As explained before, among asthma patients poor adherence levels of
controller drugs are reported and since the role played by increasing cost sharing levels in
the poor adherence has not been explored thoroughly it is important to produce more
studies in this area. In this study the role played by cost sharing levels in adherence to
controller drugs among the asthma patients having moderate persistent asthma was
investigated. Investigating impact of cost sharing on adherence levels can help to
understand the importance of cost burden as a barrier to access controller drugs.
Additionally, the study also compared patient‟s adherence levels with respect to
the cost sharing levels before they were diagnosed with moderate persistent asthma
(stepped up to dual controller therapy). This helped to determine if there is any change in
the sensitivity to the cost sharing levels after they were diagnosed with moderate
persistent asthma. According to the guidelines patients are stepped up to the dual
controller therapy when the asthma symptoms are not controlled adequately by using ICS
alone. When the patients are stepped up to the dual controller therapy, the need to be
adherent to the regimen is even greater. But on the other hand the cost burden is also
increased because of the increased number of controller drugs. Therefore, studying the
association of cost sharing with the adherence before and after the patients are stepped up
provided a more comprehensive picture of the impact of cost sharing on adherence.
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1.6 Study Limitations
The analysis was carried out using medical and pharmacy claims data bases to
examine the association of cost sharing and adherence to the controller regimen and
relationship of adherence with the health outcomes.
This study had limitations that are common to studies based on retrospective
database analysis. The MarketScan databases did not have clinical information such as
detailed asthma symptoms lung functions tests to assess the asthma severity more
accurately. Although we controlled for the demographic factors such as age and gender,
characteristics such as race and ethnicity were not available in the Market Scan databases
that might have introduced some bias to the analysis. According to the literature of
healthcare utilization, race and ethnicity are very important predictors of healthcare
utilization. Cultural differences, multiple languages influence the access of health
services. In general because of the cross-cultural difficulties and/or language barriers
people belonging to minority groups have been observed to have reduced utilization than
whites.26 Race and ethnicity are also believed to be major predictors of receiving several
treatments and procedures.27 Regarding the chronic conditions such as asthma a study
done by Agency for Healthcare Research and Quality (AHRQ) revealed that only 7% of
African Americans and only 2% of Hispanic children were prescribed routine asthma
medications compared to the 21% of Caucasians.27 However the data used for this study
did not provide any information on this key predictor of health utilization.
Regarding the demographic characteristics, the data did not allow information on
income level or availability of secondary insurance that may also significantly influences
health services utilization. It has been documented by that those who have higher income
levels have better access and therefore higher rates of healthcare utilization compared to
the poor population. Availability of secondary insurance may also influence utilization of
health services as it provides additional financial assistance along with the primary
insurance.
The adherence was measured based on the pharmacy claims for the medication
but the presence of pharmacy claim does not guarantee use of medication by the patient.
Another aspect that is not considered in this analysis is technique in using inhalation
devices. Number of asthma patients misuse their metered inhalers.28 Although by
definition they are included in the more compliant groups they might be having poor
health outcomes because of improper use of inhaler device. It is not possible to measure
outcomes attributed to the improper inhaler use by using claims database. The study also
had limitation inherent to the analysis of secondary data such as potential errors in data
collection, coding errors and omission.
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Further, this study also examined the outcomes such as Emergency Room (ER)
visits, hospitalizations and the use of Short Acting Bronchodilators (SAB) to confirm
how the better adherence is translated into better outcomes. Analyzing the cost related
non-adherence and outcomes for the patients before getting stepped up helped us to
understand if the higher cost sharing is associated with the outcomes that might result in
to worsening the severity of asthma from mild to moderate.

1.7 Terms and Definitions
Administrative claims data: Administrative claims data are the electronic
records of bills submitted by health care providers, hospitals, pharmacies, for office
visits, hospital stays, or other encounters, or for sales of drugs or supplies.
Asthma: A common disorder in which chronic inflammation of the bronchial
tubes (bronchi) resulting in swelling and narrowing the airways.
Benefit cap: Benefit caps limit the coverage for a specific amount and when the
prescription drug expenditure reached that limit, patients do not receive any coverage and
have to spend the entire cost out of pocket.
Co-morbidity index: Comorbidity index captures the combined effect of all other
diseases an individual patient might have other than the primary disease of interest.
Controller medication: Controller medications are medication that are required
to consume over a period of time to control airway inflammation and help prevent asthma
exacerbations from occurring.
Co-payment: A copayment, or copay, is a capped contribution defined in the
policy and paid by an insured person each time a medical service is accessed.
Demand curve: Demand curve is the graph illustrating the association between
the price of a certain commodity, and the amount of it that consumers are willing and
able to purchase at that given price.
Direct costs: Costs related to the provision of medical care, including the
screening, prevention, diagnosis, and treatment of diseases.29
Emergency room services: Include visits to healthcare providers in an
emergency room.
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Formulary: Formulary is a list of prescription drugs approved for coverage under
a specific health insurance plan.
Indirect costs: Costs of illness related to loss in productivity by the individual
who is ill and by family members who care for that individual.29
Medicare Part D: Medicare Part D is a federal program to subsidize the costs of
prescription drugs for Medicare beneficiaries in the United States.
Medication adherence: Adherence to (or compliance with) a medication regimen
is generally defined as, “the extent to which patients take medications as prescribed by
their health care providers.”37
Medication Possession Ratio (MPR): The Medication Possession Ratio (MPR)
is a formula used to determine compliance that is measured from the first to the last
prescription, with the denominator being the duration from index to the exhaustion of the
last prescription and the numerator being the days supplied over that period from first to
last prescription.
Moral hazard: Moral hazard is defined as the change in behavior when people
are insulated from risk.
Out of pocket costs: The portion of the claim that the patient or enrollee is
obligated to pay.
Outpatient services: Visits to physicians and other medical providers seen in
hospital outpatient departments.
Pharmacoepidemiology: Pharmacoepidemiology is the study of the use of and
the effects of drugs in large groups of people.
Prevalence: the prevalence of a disease is defined as the total number of cases of
the disease in the population at a given time, divided by the number of individuals in the
population.
Reliever medication: Asthma reliever is a drug that provides relief from asthma
symptoms and is the most commonly used asthma medication.
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Step-up therapy: When asthma symptoms are not controlled by the inhaled
corticosteroids alone patients are recommended to take additional controller medications
along with the minimum dose of ICS.

1.8 Organization of the Dissertation
This dissertation is organized into five chapters. Chapter I deals with the
introduction and problem statement along with objectives and specific aims of this study.
Chapter II provides a review of the literature covering literature on cost sharing and
asthma controller treatment options. Chapter III presents the methods used in the
research, while Chapter IV provides the results of the research. Chapter V is a discussion
of findings and possible future directions that the research may suggest.
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Chapter II: Literature Review

This chapter is organized to provide information from the current literature that
deals with cost sharing, its impact on utilization of prescription drugs and issues related
to asthma controller drug adherence.
In today‟s health care arena prescription drugs play an indispensible role.
Especially for chronic conditions such as asthma, hypertension, diabetes, prescription
drugs are instrumental in managing the disease condition and controlling symptoms.
However, the recent surge in cost of prescription drugs with double digit inflation has
worried many.31 Besides the patients consuming these drugs, major payers such as
insurance companies are most affected by the rise in cost. In order to offset the increasing
expenditure on prescription drugs, insurance companies have different strategies to
design the pharmacy benefit component.
Traditionally researchers considered healthcare as unpleasant and thus not likely
to be sensitive to price changes. However, the largest social science experiment known as
RAND Health Insurance Experiment (HIE) demonstrated phenomenon of moral hazard
even in the field of health insurance by measuring people‟s response to the price of health
care.32 Moral hazard happens when people tend to utilize more expensive medical goods
and services when they have insurance to cover the cost than when they don‟t have
insurance. This increase in spending resulting from the lower price to the user because of
insurance is called „moral hazard‟.2 RAND HIE showed that the people behave in a
different way, regarding the use of medical care and total spending, when they have
insurance. The HIE found that people who were receiving free healthcare used 30% more
healthcare than the people that had deductible.32 Same principle applies in case of
prescription drug coverage as well. Patients having prescription drug coverage are likely
to use more drugs than they would normally use because they are insulated from the
actual price. To control the moral hazard and unnecessary spending on healthcare
services, insurance companies started using cost sharing strategies such as annual
deductible and copayments. As the drug benefit plans are supplementary to the health
insurance policy different cost sharing strategies are introduced to the drug plans as well.
Initially some benefit plans implemented closed or very restrictive formularies
providing insurance coverage to only a limited number of drugs or therapeutic classes.
This led to major dissatisfaction among patients as well as health care providers such as
physicians.33 Because of the unpopularity of these plans, many insurance companies
adopted a benefit structure covering majority of drugs but classified them into different
tiers with different co-payment level. The main idea behind this arrangement was to
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encourage patients to use generic drugs or cheaper brands whenever available. From the
patient‟s perspective, depending upon what medication they are taking, out of pocket cost
is determined in the majority of insurance plans. Besides the formulary restrictions, some
plans also use benefit caps to avoid excessive drug utilization. Benefit caps limit the
coverage for a specific amount and when the prescription drug expenditure reached that
limit, patients so not receive any coverage and have to spend the entire cost out of pocket.
For example Medicare Part D beneficiaries receive coverage only up to $2400 (in 2007)
and beyond that they have to spend out of pocket until their expenditure reaches $5451.
Benefit caps also include restrictions on number of prescription drugs covered for an
individual. Medicaid beneficiaries receiving prescription drug coverage in many states
are restricted to the number of prescription drugs that can be covered. Benefit caps also
have a negative impact on utilization of prescription drugs. Soumurai et al.34 carried out a
comparison between prescription drug utilization in New Hampshire (Medicaid plan limit
of 3 drugs per month per patient) and New Jersey (no such cap existed). They found a
35% reduction in drug utilization among patients in New Hampshire.
According to the theory of economics, raising the cost sharing levels can have
following economic effects35 1) Utilization: Higher prices are expected to shift patients
upwards in the demand curve and closer to the economically optimal amount, resulting in
a decrease in utilization.2) Substitution: If the drug costs are too expensive, patients are
likely to search for less expensive alternative. For example in case of asthma, patients
might choose to consume excessive amount of short term relievers to get symptomatic
relief that are cheaper than the controllers to save money affecting the controller drug
utilization. 3) Value: A price increase would result in decrease in consumption of drugs
that are valued lower by the patients and as a result patient would be insensitive to the
price increase in high value drugs such as life sustaining drugs. However, this effect is
expected only if patients have adequate information to evaluate cost to benefit ratio
which is generally not observed.35 Therefore even though the controller drugs are
valuable to the asthma patients having moderate severity, the observed adherence levels
are still lower.
Therefore it is very important and difficult to maintain the optimum cost sharing
levels that are high enough to curb the excessive utilization but at the same time are not
discouraging patients from taking the required amount of medication.

2.1 Cost Sharing and Prescription Drugs
The literature on cost sharing for prescription drugs is comprised of a great
number of studies and articles published in various peer reviewed journals. The various
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aspects of cost sharing such as co-pay, co-insurance, formularies, tiered structure and
other methods used to control drug prices make the literature on cost sharing dispersed
across several fields and not restricted to any specific settings as in case of a medical
intervention. The literature on cost sharing mainly focuses on the impact of cost sharing
on: 1) drug spending; 2) adherence/compliance/persistence; and 3) health Outcomes.

2.1.1 Drug spending
There are experimental as well as observational studies documenting effects of
cost sharing levels on healthcare expenditure of prescription drugs at patient level. Data
published from the RAND Health Insurance Experiment (HIE) is one of the oldest
published studies in the US documenting the effect of cost sharing on expenditure.32 One
of the important findings from HIE was that individuals subject to higher coinsurance
level tend to use less care and their response to higher cost sharing in case of prescription
drugs is similar.36,37 A study done by Leibowitz et al. using the data from HIE
documented that the co-insurance at 95 % can drop the expenditure to 57% of the patients
receiving free care plan.4 Another study published from the HIE showed the patients
having free care were found to use 85% more antibiotics.36
Although the studies based on HIE used relatively older data from RAND study,
there are number of studies including some recent ones, analyzing the relationship
between co-insurance and drug spending.38-40 Almost all of the studies available in the
current literature examining the relationship between co insurance and drug spending,
have successfully documented the reduction in drug expenditure by increasing the coinsurance levels. The reduction in expenditure is observed in all age groups including
children, adults and elderly. Other than the US, studies done in other countries such as
Canada38and Sweden41 also have confirmed the finding from the US studies. The
literature on cost sharing levels and drug spending provides conclusive data on the
success of implementing cost sharing strategies on limiting the drug spending. Besides
the cost sharing strategies, several studies have also documented the success of formulary
restrictions.

2.1.2 Adherence and compliance
Adherence and compliance to the various treatments is a key issue in the health
research literature and studies on them form a vast body of literature. The studies42-44
showing cost effectiveness of prescription drugs over the other health care resources such
as ED, surgery, hospitalization etc. add to the need to study compliance and adherence
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with medications. Examples from the current literature, such as cost effectiveness of
warfarin therapy to prevent stroke,43 immunosuppressive drugs for kidney transplants,44
highlight the importance and need of examining drug utilization and factors affecting it to
achieve the maximum cost effectiveness.42
One of the most frequently cited studies on cost sharing and adherence is work
done by Goldman et al.45 In this study they used pharmacy medical claims data covering
privately insured beneficiaries aged 18-64 in 52 health plans. They examined impact of
co-payment increase with a broad range of therapeutic classes. They found an inverse
relationship between co-payment and drug utilization across all therapeutic classes they
studied. Reduction in drug utilization ranged from 25%-45%. Landsman et al. also
reported similar findings using Medication Possession Ratio (MPR) as an outcome
measure. They focused on members from managed care plans and included 9 drug classes
in their study. Key finding from this study was reduction in MPRs in 7 of 9 drug classes.
A study done by Ellis et al. examined enrollees with statin prescriptions in a managed
care organization. They also found that the statin therapy duration decreased with
increase in copayment from $10 to $20.46
However there is a repeatedly cited gap in the literature about studies focusing on
relationship between cost sharing and adherence or compliance. Many studies examining
this relationship in the US have focused on Medicaid populations, most of which have no
or very low cost sharing plans. Outside the U.S. there are several studies published in
Canada but again in Canada there are very limited variations in cost sharing as compared
to the US.
Even though the literature has considerable evidence on how increased cost
sharing results in a decrease in utilization, the current literature on cost sharing lacks
studies comparing drug classes within a clinical condition and analyzing consequent
outcomes. Such comparison provides key data for decision makers and formulary
developers in setting up cost sharing levels for a drug plan. In case of asthma, there are
very few studies published that examine the link between cost sharing and controller
regimen adherence.

2.1.3 Asthma related healthcare resources utilization outcomes
While studying adherence to different treatment regimens, it is also important to
study healthcare resources utilization outcomes to confirm that the better adherence is
translated in to better outcomes. In this section we will review studies that dealt with
effects of cost sharing on various healthcare resources utilization outcomes.
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Most of the studies evaluating effect of cost sharing on health outcomes used
health services utilization as a measure of health outcomes. Although health services
utilization is not a direct measure of health status or quality of care, increase in utilization
of services such as emergency room visits, hospitalization, inpatient and outpatient visits
indicate poor health outcomes. A number of studies15,47-49 reported no change in
utilization of relatively less expensive health services such as physician office visits,
home health visits and outpatient visits. However the cost sharing changes evaluated in
these studies were small. Furthermore the studies that did not find any association
between health services utilization and high cost sharing levels had focus on patients
suffering from a specific condition such as myocardial infarction. Study done by Pilot et
al.15 measured the effects of prescription drug cost sharing among the patients recently
hospitalized for acute myocardial infarction and therefore they may have been insensitive
to the price changes.
In terms of more expensive health services utilization such as inpatient visits or
ER visits, a study done by Christian-Herman et al.50 found that following a large change
in cost sharing levels in a Medicare HMO plan, the inpatient visits increased
significantly. Nevertheless the increase was not observed in all the diagnostic groups they
studied. No significant increase in number of inpatients visits was observed among the
patients suffering from congestive heart failure or coronary heart disease but on the other
hand patients suffering from diabetes mellitus had increased number of inpatient visits.
Another study done by Tamblyn et al.51 measured the effects of 25% raise in copayment
levels among elderly and welfare recipient in Canada. They found that patients who
reduced their consumption of essential drugs as a response to the copayment raise had
greater number of adverse events such as hospitalization, long-term care admission and
death.
A study conducted by Heisler et al.13 measured health outcomes as self reported
health status, and found that the cost related restrictions among elderly patients were
associated with decrease in their self-reported health status. They also found association
of cost related restriction and higher rates of non fatal heart attacks or stroke among those
with preexisting cardiovascular condition.
In a nutshell, cost sharing levels have mixed effects on the health outcomes such
as hospitalization, ER visit, outpatient and inpatient visits. The effects vary considerably
depending upon the disease condition focused in the study.
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2.2 Cost Sharing and Use of Asthma Medication

2.2.1 Brief description of asthma
Asthma is a chronic disorder characterized by inflammation to airway. According
to the asthma literature, asthma is one of the major causes of work and school absence.52
It has been estimated that costs resulting from lost workdays due to asthma in adults are
over $800 million per year. An additional $900 million per year is lost because of
workdays missed by parents caring for children with asthma.53 It is also one of the
common reasons leading to ER visit and hospitalization. According to a study, the
estimated annual cost of asthma-related hospitalizations is over one billion dollars54 also
the projected yearly cost of asthma-related emergency room visits is close to $300
million.53 From an economic perspective asthma costs approximately $13 billion each
year in the US.55
In terms of mortality, approximately 5000 people die of asthma in the US.52
Based on an estimate by National Center for Environmental Health (NCEH),56 there are
20 million asthma cases in the United States. According to National Institute of Allergy
and infectious diseases (NIAID),57 asthma is the most common chronic condition in
children and sixth most common chronic condition in general in the United States
Asthma is included as a key component in the respiratory disease chapter of the
Healthy People 2010 objectives.58 These objectives are: 24-1, reduce asthma deaths; 242, reduce hospitalizations for asthma; 24-3, reduce hospital emergency department visits
for asthma; 24-4, reduce activity limitations among persons with asthma; 24-5, reduce the
number of school or work days missed by persons with asthma because of their asthma;
24-6, increase the proportion of persons with asthma who receive formal patient
education, including information regarding community and self-help resources, as an
essential part of the management of their condition; 24-7, increase the proportion of
persons with asthma who receive appropriate asthma care according to the NAEPP
guidelines; and 24-8, establish in greater than 25 states a surveillance system for tracking
asthma deaths, illnesses, disabilities, impact of occupational and environmental factors on
asthma, access to medical care, and asthma management.58

2.2.2 Asthma severity classification
NHLBI classifies asthma by its severity. The classification based on severity is
widely used by health care professionals. As asthma treatment choice is largely
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dependent upon the severity levels, it is useful to briefly review the asthma severity
levels. These severity levels are based on frequency and severity of asthma symptoms.
The severity levels according to NHLBI guidelines are outlined in Table 1.
Treatment regimens for children and adults (age 5 and above) are decided based
on the severity level. Patients having mild intermittent asthma are mostly treated with
quick-relief medicines only, while patients having severe persistent asthma are treated
with combination therapy of one or more daily controller medicines along with the use of
quick-relief medicines as needed.

2.2.3 Asthma treatment options
Although asthma can‟t be cured, it can be controlled. Current guidelines also
recommend treatment for asthma to be focused on controlling the inflammation.
Monitoring the symptoms and avoiding asthma triggers is considered to be the first step
in asthma control. Besides avoiding the asthma triggers, guidelines recommend use of
medications to achieve adequate control. The asthma medications are broadly categorized
in two types of drugs: 1) quick relief medications, and 2) long term control medications.
The quick relief medications are short acting bronchodilators such as metaproterenol
(Alupent, Metaprel), ephedrine, terbutaline (Brethaire) and albuterol (Proventil,
Ventolin). The long term control medication are inhaled or orally administered anti
inflammatory steroid such as unisolide (AeroBid), triamcinolone (Azmacort) and
beclomethasone (Beclovent and Vaceril), Long-acting inhaled 2-agonist (LABA) and
Leukotrine receptor Antagonist (LTRA),Theophylin etc.
The short acting medications are known to produce symptomatic relief but they
do not contribute in controlling the chronic inflammation itself in asthma cases. However
the controller drugs do not show immediate symptomatic relief but help in controlling the
chronic inflammation itself. Because of these properties, the short acting dilators are
being recommended for „as needed‟ or „rescue‟ basis only.8 Patients having persistent
asthma are advised to take both classes of medication.
Within the controller medications, ICS are proven to be most effective and
patients are suggested to start with minimum possible dose of ICS therapy. For the
patients that require more control, guidelines recommend addition of LABA or LTRA to
the existing dose of ICS. The clinical evidence is not conclusive towards any of these add
on therapies as the clear dominant over another.
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Table 1 Asthma severity definition according to NHLBI guidelines
Asthma
Severity

Intermittent

Symptoms

≤ 2 days/week

Nighttime
awakenings

≤ 2x /month

Persistent
Moderate

Severe

> 2 days/week
but not daily

Daily

Throughout
the day

3-4x/month

> 1x/week but
not nightly

Often
7x/week

Mild

SAB use for
symptom
control

≤ 2 days/week

> 2 days/week
but > 1x /day

Daily

Several
times per
day

Interference
with normal
activity

None

Minor
limitation

Some
limitation

Extremely
limited

Source: National Heart, Lung and Blood Institute (NHLBI) Clinical practice guidelines,
Expert Panel Report 2: guidelines for the diagnosis and management of asthma. 2008.9

21

2.2.3.1 Add on therapy with LABA
LABA are potent airway dilators and have a long term effect of chronic
obstruction caused by asthma. Combining a LABA with an ICS has shown a greater
improvement in the control of symptoms and in lung function than doubling the dose of
the ICS59,60 A double-blind, randomized, parallel-group study involving 852 patients
done by Pauwels et el60 demonstrated that, the rates of severe and mild exacerbations
were decreased by 26% to 40%, when formoterol (LABA) was added to the lower dose
of budesonide (ICS). A study known as GOAL study has confirmed this data by
conducting a randomized, double-blind, parallel-group study of 3,421 patients with
uncontrolled asthma.61 This study concluded that asthma patients achieved control on
asthma symptoms with combination of inhaled Salemterol/fluticasone (LABA+ICS)
more rapidly and at a lower dose of corticosteroid than with combination of inhaled
fluticasone (ICS) alone.

2.2.3.2 Add on therapy with LTRA
Leukotriene receptor antagonists (LTRA) are oral medications that act by
blocking chemical mediators that can lead to inflammation in the airways. LTRA work to
suppress the airway inflammation and thus produce mild bronchodilation.62 Several
studies have demonstrated efficacy of LTRA along with low doses of ICS in both adults
and children.63,64 In a study called as COMPACT (Clinical Outcomes with Montelukast
as a Partner Agent to Corticosteroid Therapy) study, Price et al.65 demonstrated the
efficacy of Montelukast as adjunct to Budesonide (ICS). A recent placebo controlled
study involving 639 patients on Montelukast (LTRA) for 16 weeks showed decrease in
the exacerbation frequency.66
Even though the safety and efficacy of adding LTRA is established in the current
literature, the relative efficacy to addition of LABA is questioned. A study done by Busse
and coworkers67 compared the addition of salmeterol (LABA) or zafirlukast (LTRA) to
low doses of inhaled corticosteroids, found considerably better improvement in lung
function and symptom control with the addition of the LABA as compared with a LTRA.
There are also a few studies68-70 documenting no additive benefit of LTRA in asthma.

2.2.4 Adherence to asthma controller drugs
With the projected $13 billion in direct and indirect costs asthma puts a
significant burden on US economy. To achieve the best control over asthma, continuous
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treatment that avoids recurring exacerbations is very important. Although asthma is
considered as mild illness which should be managed by ambulatory care, the one third of
the total direct costs is related to emergency department use and hospitalization.71 Lately
a study showed that a large portion of these costs are attributable to the uncontrolled
asthma. According to the study, primary reason behind the uncontrolled asthma is
underuse of prescribed therapies such as asthma controller drugs.71 Despite the
recommendations from national guidelines, several studies have reported poor average
rates of adherence to the controller medications among children72-74 as well as adult
populations75,76 suffering from asthma.
A study done by Legorreta et al.76 found that overall, adherence to National
Asthma Education Program (NAEP) guidelines was poor especially with the use of
preventive drugs. Furthermore the survey respondents that indicated to have asthma
inhaler, only 54% of them used it daily. Factors such as age (older), duration of asthma
(longer), increasing current severity of disease, were found to be associated with the
controller drug use. Jatulis et al.75 analyzed adherence to the National Heart, Lung, and
Blood Institute (NHLBI) guidelines in California and they also found low level of antiinflammatory steroids usage despite the emphasis in guidelines.
Lower adherence to the controller drugs is also observed among asthma patient
with the moderate to severe asthma levels. These patients are in more need of controller
drugs and lack of controller drug use makes them more vulnerable to the asthma related
morbidity and mortality. A study called as TNEOR focused on patients with moderate or
severe asthma categories and found the lack of control in the study population.
The literature on asthma controller medication adherence strongly indicates a
significant lack of adherence to the controller drugs among asthma patient populations
across all age groups and asthma severity levels. Also enough evidence was found from
current literature correlating the lack of adherence to the controller drug with the
increased consumption of the other healthcare services such as ER visits and worsening
of the heath status of asthma patients.

2.2.5 Adherence measures
In this study we used MPR to measure adherence to the asthma treatment
regimen. However, various different methods are also used to assess the treatment
adherence. Traditionally the methods used were pill counting, journals, electronic
measurement devices, biochemical tracers, questionnaires and more recently analysis of
pharmacy claims databases are used to assess the adherence to treatment regimens.
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Studies that use self reported adherence methods ask patients whether they missed doses
and also reasons if they ever missed any.77 Patients are required to mention their current
prescriptions and the average number of tablets missed per day, week, and month. The
strength of this method lies in its fast and easy format to administer and it also offers
thorough information about utilization patterns, patient perception of treatment and
barriers to access of treatment. However, weakness of this technique is it relies on
patient‟s memory and honesty. In case of asthma medication utilization Brooks et al.77
developed a multi-item, self-reported scale to assess patient adherence to the asthma
inhalers. This scale was supported by the results and because it takes less than five
minutes to complete, it also demonstrated ease of use.
More recently the widely used method to calculate adherence is to conduct
retrospective analysis of insurance claims databases. Analyzing claims data has been
suggested as an appropriate method for several measures such as assessment of quality of
care, research in pharmacoepidemiology, evaluation of health care appropriateness and
also cost and utilization studies.78 When direct measurement of utilization is not feasible,
pharmacy claims databases are recommended as most appropriate to measure adherence
and compliance.78 Several studies78-80 recommend use of pharmacy claims data to
evaluate medication compliance and adherence. The adherence rate given by
administrative data does not provide direct information on medication utilization
information, but rather provides evaluation of medication possession. Adherence
calculations using administrative claims data are based on the assumption that that
patients use the drug as prescribed from the day of dispensing, and use all medications
obtained. Therefore administrative data can offer the investigator only an estimate of the
maximum possible level of medication utilization.81
To measure the adherence using large claims data as source, Sclar et al.82
introduced Medication Possession Ratio (MPR). Followed by their work the MPR in now
widely accepted as a measurement of drug adherence.83 Most of the times the MPR is
defined as the ratio of „sum of the days' supply of medication‟ to „the total number of
days in the study period.‟ This ratio yields values ranging from 0 to 1. MPR successfully
captures the utilization behavior however it fails short to capture characteristics such as
timeliness and consistency. For example if a patient fills prescription every alternate
month throughout the year and another patient fills prescription for six months only then
even though their utilization behavior is different both of them will have exact same
value for the MPR.
Besides MPR, literature search on adherence measurement using pharmacy claims
database also showed several methods to measure medication adherence. Some of the
most frequently cited measures include, Continuous Measure of Medication Acquisition
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(CMA); Continuous Multiple Interval Measure of Oversupply (CMOS); Medication
Refill Adherence (MRA); Continuous Measure of Medication Gaps (CMG); Continuous,
Single Interval Measure of Medication Acquisition (CSA); Proportion of Days Covered
(PDC); Refill Compliance Rate (RCR); Medication Possession Ratio, modified (MPRm);
Dates Between Fills Adherence Rate (DBR); and Compliance Rate (CR). Hess et al.81
reviewed studies based on all these measures and concluded that CMA, CMOS. MPR and
MRA produce identical results in measuring adherence while CMG and PDC produce
slightly lower and CR, MPRm, RCR and CSA produce higher rates of adherence.

2.2.6 Cost sharing and controller drugs utilization
Although cost sharing plays an important role in adherence to the medications for
chronic conditions, the effect of it among asthma population is not been explored
extensively. Despite the poor adherence levels are reported abundantly in the current
literature, there is limited information available on association of it with the cost sharing
levels. Also the currently available studies focusing on cost sharing and utilization of
asthma medication did not assess utilization of asthma drugs using adherence measures
such as MPR.
When searching for the articles on costs sharing effects and asthma controller
utilization, only two major studies were found in the US. Interestingly, the results from
both the studies were contradictory to each other. First study found that although the cost
sharing levels increased from 1995 to 2000, utilization of controller drugs among
asthmatics was not affected significantly.25 Conversely another study done by Goldman
et al.45 explored relationship of cost sharing and utilization of prescription drugs among
multiple chronic conditions (based on drug classification in the red book) found that
doubling the cost sharing levels resulted in to 32% drop in overall asthma drug
utilization. None of these studies specifically focused on the asthmatics with asthma
severity levels „moderate to severe‟ (patients that need more that one controller drugs).
Also both the studies did not capture effects of cost sharing levels on health outcomes
such as emergency room visits, hospitalization and SAB utilization. In terms of cost
sharing effects on utilization of asthma medications among children, Ungar et al.84 did a
study focusing on cost sharing effects on asthma medication utilization among children in
Ontario, Canada. In this study they found that the cost sharing levels affected
consumption of asthma medication among children. Higher cost sharing levels resulted in
to significantly lower consumption of asthma medications such as controller drugs.
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2.3 Gaps Addressed by This Study
Work done prior to this study has provided important information about cost
sharing and its impact on various factors such as drug spending, drug utilization and
adherence to the treatment regimen. However when it comes to impact of cost sharing on
adherence to medication within a chronic condition such asthma, there are very few
studies available. The literature on adherence with asthma controllers has documented the
lower adherence to controller regimen than the recommended guidelines, but there are a
limited number of studies examining the association of lower utilization to the out of
pocket cost. Also the results from previous studies are not consistent with each other and
do not measure utilization of medications using standardized adherence measures such as
MPR. Poor adherence to controller regimen is characterized by increased morbidity,
mortality and increased utilization of health care resources. This gap can be bridged by
adding more studies to the current literature that establish the link between cost sharing
and adherence to medication with respect to a particular chronic condition such as
asthma.
Rising costs of prescription drugs are accelerating the need to introduce greater
cost sharing in US managed care programs but the information on how successful these
policies would be to control the overall cost and improve the health status is limited. In
case of chronic conditions such as asthma, prescription drugs comprise an important part
of treatment and management of the disease. In this study we focused on the asthma
patients having moderate to severe asthma levels and analyzed what impact cost sharing
has on the utilization of controller drugs.
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Chapter III: Methods

The main focus of this study was to evaluate the impact of prescription drug cost
sharing on utilization of asthma controller medications and to analyze the health
outcomes associated with the utilization of controller drugs. The study population
included asthma patients from an administrative claims data within the age group 5-65
who are stepped up from single controller therapy to the dual controller therapy.
To investigate the impact of cost sharing on adherence to the treatment options we
utilized retrospective longitudinal study design using administrative claims database. This
was an observational study and the data for this study came from MarketScan
commercial database. The study period for each patient started six months prior to the
patient‟s index medication and continued for six months post index. The asthma patients
were defined to be diagnosed with „moderate persistent‟ asthma if they were stepped up
from one controller medication to more than one controller medications. Whether the
patients were stepped up or not was determined by analyzing their prescription drug
records.

3.1 Study Design
The asthma patients having prescription drug history of only one controller (ICS)
were selected among them those who were found to have additional controller drug (ICS
+ LABA or ICS + LTRA) in the claims history were selected for the study. Controller
drug utilization pattern for these patients before and after getting stepped up was studied
using MPR as the adherence measure. Presence of additional controller medication (ICS
+ LABA or ICS + LTRA) was the index date prescription and 6 months prior and after
the index date defined the study period. Figure 2 illustrates the research design used in
this study.
To investigate the impact of cost sharing on adherence to the treatment options we
utilized retrospective longitudinal study design using administrative claims database. This
was an observational study and the data for this study came from MarketScan
commercial database. The study period for each patient started six months prior to the
patient‟s index medication and continued for six months post index (Figure 2). The
asthma patients were defined to be diagnosed with „moderate persistent‟ asthma if they
were stepped up from one controller medication to more than one controller medications.
Whether the patients were stepped up or not was determined by analyzing their
prescription drug records.
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Figure 2 Study design
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The asthma patients having prescription drug history of only one controller (ICS)
were selected among them those who were found to have additional controller drug (ICS
+ LABA or ICS + LTRA) in the claims history were selected for the study. Controller
drug utilization pattern for these patients before and after getting stepped up was studied
using MPR as the adherence measure. Presence of additional controller medication (ICS
+ LABA or ICS + LTRA) was the index date prescription and 6 months prior and after
the index date defined the study period.

3.2 Study Population
For this study we needed patients diagnosed with asthma and who are stepped up
from a single controller drug (ICS) to a combination of ICS + LABA or LTRA. To
formulate the final study sample, we applied following inclusion and exclusion criterions.

3.2.1 Inclusion criteria
The participants for this study were selected based on their principal or secondary
diagnostic claim (ICD-9 493.XX) for asthma during the pre index period. All subjects
included for this study were in the age group from 5 to 65. All asthma patients having at
least one claim of ICS and no claims for any other controller add-on were recruited for
the final sampling. Among these patients those that were found to have at least one
additional prescription of LABA or LTRA along with at least one claim for ICS were
included in the final sample.

3.2.2 Exclusion criteria
To ensure the evaluation of patient outcomes is based on asthma; patients were
excluded from analysis if they were diagnosed with any of the following conditions in the
pre or post study period. The conditions included chronic obstructive pulmonary disease
(COPD), bronchopulmonary dysplasia and respiratory distress syndrome. Also the
patients that switched medications from one controller add on to another controller add
on were excluded from this analysis. Patients not enrolled continuously for the study
period were also excluded from the study.
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3.3 Data Source
This study utilized data from the Medstat MarketScan databases (Copyright 2001,
The Medstat Group, Inc., All Rights Reserved.) The MarketScan databases are based on
privately insured paid medical and prescription drug claims. The data is collected from
approximately 45 large employers, health plans, and government and public
organizations on person specific clinical utilization, expenditures, and enrollment across
inpatient, outpatient, prescription drug, and carve-out services. Including the commercial
insurance companies the databases consist of data from almost 100 payers.
The MarketScan Databases are based on a calendar year incurred period and are
produced as a snapshot in time. The databases are created by combining the standard
variables of the individual databases (data contributors) and also links between years of
data are established across all data types. The amount of time between the date of service
on the claim and the date payment is made, also known as Claims lag periods fluctuate
considerably across the roughly 100 insurance carriers in MarketScan. Because of this,
the data are collected when close to 100% of claims have been paid, which takes about
six months after year end.
Various edits and checks are done to confirm the reasonableness and validity of
the data. Reasonableness is established by checking the relationship between two or more
fields against norms. For selected fields, including zip codes, diagnosis codes, procedure
codes, date(s) of service, gender and age, validity checks are carries out to compare
recorded values to lists of probable valid values for those fields. The improper coding is
fixed by flagging and recommending it to the carrier or data processor for quality
improvement actions.

3.4 Measures
According to the theoretical framework of this study we first measured effect of
cost sharing levels (Exposure variable) on controller drug adherence (intermediate
outcome) and then measured effect of adherence on health outcomes such as ER visits,
hospitalization and SAB use (End outcomes). Variables that can be predisposing for
asthma drug utilization18 and also were available in databases included age gender and
location. Data on race and ethnicity could not be obtained because of the limitation of
administrative claims databases. Cultural differences, multiple languages influence the
access of health services. In general because of the cross-cultural difficulties and/or
language barriers people belonging to minority groups have been observed to have
reduced utilization than whites.26 It has been documented that the race and ethnicity are
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major predictors of receiving several procedures and treatments. In one study
investigators found that out of nine hospital procedures only five procedures were
significantly less common among African American patients than among Caucasian
patients. Other AHRQ studies have also revealed that the additional disparities exist for
various chronic conditions including asthma. Regarding the use of necessary medications
among pediatric asthma patients compared to 21% of Caucasian patients only 7%
Afirican American and 2% of Hispanic children were prescribed routine asthma
medication to prevent the asthma related. However, as the insurance claims data do not
allow information on race and ethnicity, the exclusion of this measure is a source of possible
bias in the estimates due to the correlation of race/ethnicity with measures included in the
model.
In terms of enabling resources besides the cost sharing levels study included type
of health plan and pre index healthcare expenditure. For this study, the target population
represented similar illness level i.e. moderate persistent asthma. In order to control for the
presence of comorbid conditions which can influence the overall drug utilization85, we
used Charlson‟s modified comorbodity index86 adapted for administrative claims
databases.

3.4.1 Exposure variable
Cost sharing levels: Cost sharing levels were defined by determining percentage
of total cost paid by the patients out of pocket. Depending upon the percentage of total
cost paid out of pocket patients were categorized in to four categories. These categories
were defined as 0-10%, 11-20%, 21-34% and >35% of total cost paid out of pocket.

3.4.2 Outcome variables
Medication Possession Ratio (MPR): To measure the adherence to controller
drugs, Medication Possession Ratio (MPR) was used. The MPR is a continuous variable
assessing medication availability over multiple refill intervals. It is calculated by dividing
the number of days supplied for a given medication by the number of days in the study.
Possible values for MPR are between 1.0 and 0, 1 indicating highest compliance and 0
indicating lowest possible compliance. MPR is used frequently in studies as a measure of
compliance. The MPR provides information about whether the patient is using the proper
amount of medication in a specific timeframe. In this study, MPR for the medications
was calculated by dividing the number of days of supply of medication received during
180 days of follow-up. The relative MPR was determined by calculating the overall
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median MPR as reference to the individual MPR. For the analysis purpose, based on the
median, patients were dichotomized in to more or less persistent users (Figure 3).
In terms healthcare resources utilization outcomes, ED visits and hospitalization
among the study population were used as indicators for the health outcomes. Number of
ED visits and hospitalizations were calculated for all the study participants and compared
between the patients having different adherence. The total number of ED visits was
summed up from the outpatient and inpatient records and total number of hospital stay
days was calculated based on asthma related inpatient records. Besides ED visits and
hospitalizations, utilization of SABs was also measured. Over utilization of SAB
indicates the more frequent asthma symptoms and therefore indicating the poor control
on the asthma. The current asthma treatment focuses on use of controllers to reduce the
asthma symptoms which reduces utilization of SABs.

3.4.3 Control variables
Age, gender, geographical location, prescription drug expenditure, Charlson‟s comorbidity index were used as control variables. Age gender and location provided
information about predisposing characteristics in the Anderson‟s healthcare utilization
model. Pre-index total healthcare expenditure (inpatient and outpatient) for six months
period was calculated for each patient. It served as an enabling factor since it indicates
patients‟ financial ability to pay the cost out of pocket.
Other than the health care expenditure, type of plan variable was also included as
enabling variable. Subjects were categorized in to fee-for-service and non-non-fee for
service plans based on the type of plan they were enrolled in. Non-Fee-for-service plans
included health maintenance organizations, noncapitated point-of-service plans, preferred
provider organization, or capitated or partially captitated point-of-service plans. Fee-forservices plans included basic medical and comprehensive health insurance coverage.

3.4.4 Charlson’s comorbidity index
Aggregate comorbidity measures are important to attribute risk factors and
disease severity of the patient. In order to successfully implement the „need‟ part of
Anderson‟s healthcare utilization model, it is necessary to attribute severity levels based
on comorbid conditions. A Charlson Index score,86 modified for use in administrative
databases,85 was calculated for each individual patient, using ICD-9 CM codes in the
15 secondary diagnosis field (Table 2).
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Figure 3 Example of MPR calculation
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Table 2 Comorbidity weights
Weights

Conditions

ICD-9 Codes

1

Myocardial infarct

410, 411

Congestive heart failure

398, 402, 428

Peripheral vascular disease

440-447

Dementia

290, 291, 294

Cerebrovascular disease

430-433, 435

Chronic pulmonary disease

491-493

Connective tissue disease

710, 714, 725

Ulcer disease

53 l-534

Mild liver disease

571, 573

Hemiplegia

342, 434, 436, 437

Moderate or severe renal disease

403, 404, 580-586

Diabetes

250

Any tumor

140-195

Leukemia

204-208

Lymphoma

200, 202, 203

3

Moderate or severe liver disease

070, 570, 572

6

Metastatic solid tumor

196-199

Source: D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the
Charlson comorbidity index with administrative data bases. Journal of Clinical
Epidemiology 1996 December; 49(12):1429-33.85
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The Charlson comorbidity index was originally designed as a measure of the risk
of 1-year mortality attributable to comorbidity in a longitudinal study of general
hospitalized patients. The measure was then validated for the same outcome in a cohort of
breast cancer patients. Cox proportional hazard modeling was used to create its contents
and weighting scheme.86 Later on it was adapted in a way that International
Classification of Diseases, Ninth Revision (ICD-9), codes could be used to compute the
Charlson Comorbidity Index with existing administrative data85. Using the ICD codes
from the outpatient‟s claims for the primary or secondary diagnoses by the study
population, weights were applied and individual comorbidity scores were assigned to all
the study participants

3.5 Statistical Analysis

3.5.1 Cost sharing levels and adherence
Accurately assessing the impact of cost sharing levels on adherence with
controller drugs requires rich data source and advanced statistical techniques. Regression
modeling, statistical tests such as student t test and use of statistical software SAS
(version 9.1) helped to achieve the results for this study. This methodology provided
important information that will be essential in targeting future strategies to improve the
controller drug utilization among asthma population.
To quantify the change in Medication Possession Ratio (adherence measure) with
respect to increase in cost sharing level, multivariate least square linear regression model
was built. All study participants were categorized into cost sharing levels (0-10%, 1120%, 21-35% and >36%) calculated by percentage of total cost of a drug paid out of
pocket and the change in adherence was evaluated. Cost sharing levels was the
independent variable of interest in this model. The model was adjusted for
covariates/independent variables available from the data such as gender, age past year
expenditure on prescription drugs and Charlson comorbidity index. Age was squared and
also included in the model as usually age has a curvilinear relationship with utilization of
health services. The past year expenditure was log transformed to reduce the influence of
outliers. This helped to reduce skewness of the distribution and bring it close to normal
distribution.

Yi = β0 + β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5
Where, i = 1,..., n
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Y = Adherence to controller drugs (MPR)
x1 = Cost sharing levels
x2 = Gender
x3 = Age
x4 = Past year expenditure
x5 = Charlson comorbidity index
A similar regression model was built to analyze if the regression coefficient varies
across patients that used ICS+LABA and ICS+LTRA.

3.5.2 Adherence and resource utilization outcomes
Once the relationship between cost sharing levels and adherence to controller
drugs was analyzed, the asthma related health care services utilization outcomes
relationship with the adherence level was analyzed by controlling the covariates. Since
the adherence is also a function of some variables, it is an endogenous variable. The
endogenous explanatory variable makes a non-zero correlation with the error term in the
health care utilization regression.
In cases where such correlation occurs ordinary linear regression models
generally produces biased estimates. To overcome this problem, if an instrument is
available and used, consistent estimates may still be obtained. An instrument is a variable
that correlated with the endogenous explanatory variable but does not itself have any
direct impact on healthcare utilization variables.87
So finally to estimate the unbiased results, a two stage least square regression
equation was built. In the first stage, the endogenous adherence variable was regressed on
prescription drug cost sharing plus all explanatory variables in the health care service
utilization regression equation. Since the cost sharing levels for prescription drug may
influence adherence with controller drugs, it may not have any direct influence on other
resource utilization such as ER visits and hospitalization. Thus, it qualifies as an
instrument. From this equation, the inverse mills ration was obtained. In the second stage,
each healthcare service utilization variables were regressed on the adherence variable,
and other covariates plus the inverse mills ratio created in the first stage.
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Yi = β0 + β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5 + β5 xi6 + ei
Where, i = 1,..., n
Y = Number of ER Visits
x1 = Predicted value of MPR
x2 = Gender
x3 = Age
x4 = (Age)2
x5 = Log (Past year expenditure)
x6 = Charlson comorbidity index

Yi = β0 +β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5+ β5 xi6 + ei
Where, i = 1,..., n
Y = Hospitalization
x1 = Predicted value of MPR
x2 = Gender
x3 = Age
x4 = (Age)2
x5 = Log (Past year expenditure)
x6 = Charlson comorbidity index

Yi = β0 + β1 xi1 + β2 xi2 + β3 xi3 + β4 xi4 + β5 xi5 + β5 xi6 + ei
Where, i = 1,..., n
Y = SAB use
x1 = Predicted value of MPR
37

x2 = Gender
x3 = Age
x4 = (Age)2
x5 = Log (Past year expenditure)
x6 = Charlson comorbidity index
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Chapter IV: Results

4.1 Sample Selection and Sample Characteristics
Based on the diagnostic codes on the outpatient‟s claims data, total 89,766
patients were identified to have asthma. After analyzing prescription drugs claims of
these patients for the recruiting period (July 2000 to July 2001), 7,941 patients were
found to use either LABA or LTRA prescription(s). Prescription drug claims for these
patients were further analyzed for six months prior to the first occurrence of either LABA
or LTRA prescription and 3.466 patients were found to have no evidence of LABA or
LTRA use and also evidence of ICS use.
These patients were categorized as stepped up patients and by analyzing their
enrollment records only those patients were selected that were continuously enrolled in a
health plan for the entire study period (pre-index and post-index period). Further, patients
that had evidence of switching from one add on to another during the post index period
were excluded from the study. Patients that were diagnosed with chronic obstructive
pulmonary disease (COPD), bronchopulmonary dysplasia and respiratory distress
syndrome were also excluded. Finally patients below age 5 were excluded to form the
final study sample of 1447 patients (Table 3).
In terms of demographic characteristics (Table 4), the study sample had more
females than males with average age of 37(SD 19.17). Majority of them were located in
north central (35.52%), north east (25.22%) and south (33.31%) with relatively lower
percentage of residents (5.94%) from the west region. In terms of Charlson‟s comorbidity scores, values ranged from minimum 0 to maximum 11. Charlson‟s
comorbidity scores were assigned based on the number of comorbid conditions present
besides asthma multiplied by weights assigned to each comorbid condition Most number
of subjects had a comorbidity score in the range of 0-3 while about 10% of the total study
population had a comorbidity score higher than 3.
The cost sharing levels were defined by determining percentage of total cost paid
by the patients out of pocket Patients were categorized into four categories.: 0-10%, 1120%, 21-34% and >35% of total cost paid out of pocket. Patients that paid more than
35% out of pocket were lesser in number (3.73%) while all other categories had close to
30% patients.
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Table 3 Sample selection criteria

Sample Selection Criteria

Number of
Number of Patients
Patients Dropped
Remaining

Total number of patients with an asthma
diagnosis on a outpatient claim

0

89,766

Evidence of using ICS

65,470

24,296

Evidence of LABA/LTRA in the
recruiting period, but no evidence of
LABA/LTRA use in the pre-index
period

21,510

2,339

Continuous enrollment in the total study
period

447

1,892

No evidence of switching from one addon drug to another add-on drug

248

1,644

No evidence of other respiratory
conditions

97

1,547

Patients between age 5 and 65

100

1,447
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Table 4 Sample characteristics
Variable

Asthma Patients (% or $)

Gender (%)
Male
Female
Total

582 (40.22)
865 (59.78)
1,447

Mean Age (SD)

37.27 (19.17)

Geographical Region (%)
Northeast
North Central
South
West

365 (25.22)
514 (35.52)
482 (33.31)
86 (5.94)

Pre-Index Average
Healthcare Expenditure
(SD)

$1,623.51 ($3,597.08)

Comorbidity Score (%)
0
1
2
3
4 and above

682 (41.13)
427 (29.51)
201 (13.89)
78 (5.39)
59 (4.13)

Cost Sharing Levels (%)
0-10%
11-20%
21-35%
36% and more

433 (29.94)
485 (33.54)
474 (32.78)
54 (3.73)

Plan Type (%)
Non-Fee-for-Service Plan
Fee-for-Service Plan

1,125 (77.75)
322 (22.25)
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4.2 Multivariate Regression Analysis
Multivariate regression analysis carried out to analyze relationship between cost
sharing levels and combined adherence to ICS+LABA/LTRA. This analysis (Table 5)
showed a negative association between cost sharing levels and adherence to the controller
regimen among the study population. Multiple dummy variables with different cost
sharing levels were used to analyze effect of cost sharing levels (0-10%, 11-20%, 21-35%
and >36%) on adherence to the controller drugs.
The 0-10% cost sharing level was used as reference group and change in the
adherence was measured. Results showed that patients having co-pay levels at 11-20%
had a 5% decrease (β = -0.05153 p = 0.006) in adherence while patients having 21-35%
co-pay had a 12% decrease in adherence compared to the patients having 0-10% co-pay.
Asthma patient that paid more than 36% cost out of pocket had the lowest rate of
adherence (β = -0.1906 p = <0.001) demonstrating overall drop in adherence with
increase in co-pay levels. The null hypothesis for this analysis was that the adherence
levels would not be affected by changes in the cost sharing. However, since significant
drop in adherence with respect to the cost sharing levels was observed, null hypothesis
was rejected.
In terms of other demographic characteristics, compared to the patients from
south, patients in all other regions (Northeast - β = 0.029 p = 0.0649 North Central β =
0.0571 p = 0.004 West β =0.081 p = 0.0027) were found to be more adherent to the ICS
regimen. Charlson‟s co-morbidity score (β = 0.004 p =0.346) and gender (β = -0.01995 p
= 0.1207) had a statistically insignificant association with the adherence while pre index
health care expenditure had a negative association (β = -0.0051 p = 0.0207) Compared to
fee for service plans, patients in non fee for service plans were found to have better
adherence. (β = -0.0966 -p = <0.001) The parameter estimate for age variable was
negative (β = -0.0061 -p = <0.001) while the estimate for age square was positive (β = 0.00011 -p = < 0.001) showing a curvilinear relationship with the controller adherence.
Analysis of ICS adherence and cost sharing association before and after index
period (Table 6) showed an increased magnitude of negative association in post index
period (β -0.005 p = <0.001). The null hypothesis here was that there would not be any
change in controller adherence with respect to the cost sharing levels. However as the
analysis showed an increased magnitude of negative association, showing an increased
sensitivity to the cost sharing the null hypothesis was rejected
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Table 5 Multivariate regression: association between cost sharing and combined
controller (ICS+LABA/ LTRA) adherence
Variable

Parameter Estimate

P-Value

11-20%
21-35%

-0.05153
-0.12096

0.006*
<.0001*

36% and more

-0.19069

<.0001*

Age
Age Square

-0.00661
0.00011483

<.0001*
<.0001*

-0.01995

0.1207

Northeast

0.02956

0.0649

North Central

0.05714

0.0004*

West
Pre-Index Healthcare
Expenditure

0.08105

0.0027*

-0.0051

0.0207*

Comorbidity Index
Plan Type
Non Fee-for-Service plan
(Reference)

0.00486

0.3467

Fee- for-Service Plan

-0.0966

<.0001*

Cost sharing level
0-10% (Reference)

Gender
Male (Reference)
Female
Region
South (Reference)

* Statistically significant

at 0.05 alpha

n: 1442 R-Square: 0.47
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Table 6 Multivariate regression: association between cost sharing and steroid adherence
in the pre-index and post-index period
ICS Adherence Pre-index ICS Adherence Post-index
Variable

Cost Sharing
Age

Parameter
Estimate

P-Value

Parameter
Estimate

P-Value

-0.00484

<.0001*

-0.00566

<.0001*

-0.00075245

0.634

-0.00184

0.2881

0.00006515

0.0085

*

Age Square

0.00004453

0.0488

Gender
Male (Reference)
Female

-0.0159

0.2158

-0.01704

0.2254

0.02487

0.1201

0.01631

0.3514

North Central

0.05469

0.0007

*

0.05487

0.0018*

West

0.08253

0.0022*

0.08057

0.0064*

Pre-Index Healthcare
Expenditure

-0.00586

0.0078*

-0.0062

0.0101*

Comorbidity Index

0.004

0.4382

0.00288

0.61

Plan Type
Non-Fee-for-Service
(Reference)
Fee- for-Service Plan

-0.08797

<.0001*

-0.10568

<.0001*

Region
South (Reference)
Northeast

* Statistically significant at 0.05 alpha
ICS = Inhaled Corticosteroids
n: 1442 R-Square: 0.48
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4.3 Comparison of Regression Co-efficient between ICS+LABA and
ICS+LTRA
To compare the change adherence levels with respect to cost sharing between
ICS+LABA and ICS+LTRA users, two regression models were built to obtain two
different regression coefficients. Both the models included cost sharing as a continuous
variable. The total sample had 898 (62.0%) patients that were prescribed ICS+LABA
while 549(37.94%) patients were prescribed ICS+LTRA therapy (Table 7).
In terms of pre-index characteristics, subjects in ICS+LTRA group were less
likely to be females and younger in age than the ICS+LABA group. These differences
were appropriately controlled in the multivariate regression models.
ICA+ LABA cohort produced a slightly lower regression coefficient (β = -0.0042
p = <0.001) than the ICS+LTRA cohort (β = -0.005 p = <0.002) demonstrating the
difference in adherence levels as a response to co pay level (Table 8). Both the
coefficients were tested using Student t-test to find out if the difference between them is
statistically significant. The t-test result showed a statistically significant difference
between these two values.
The null hypothesis in this case was that there would not be any difference in the
cost sensitivity for these two options. However, since there was significant difference in
the cost sensitivity between the ICS+LABA and ICS+LTRA sub groups, null hypothesis
was rejected.

4.4 Adherence and Healthcare Resources Utilization
Among the study population, 140 (9.68%) patients had at least one asthma related
ER visit in the post index period while 67 (4.6%) patients had at least one asthma related
hospitalization in the post index period (Table 9).
Based on the data from outpatient, inpatient and prescription drug claims, total
number of ER visits, days spent in hospital and number of SAB prescriptions used was
calculated for each individual patient. About 9% of the patients in each cohort had at least
one ER visit. Close to 4% patients in ICS+LABA cohort had at least one hospitalization
while 5.46% of patients had at least one hospitalization. SAB use was also similar in two
cohorts with average of 2.12 prescriptions in ICS+LABA group and 2.47 prescriptions in
ICS+LTRA group. Controller adherence was slightly better (48% MPR) in ICS+LTRA
group compared to the ICS+LABA group (43% MPR)
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Table 7 Pre-index characteristics for ICS+LABA and ICS+LTRA cohorts
Variable

ICS + LABA

ICS+ LTRA

0.002a

Gender (%)
Male
Female
Total
Mean Age
Geographical Region
(%)
Northeast
North Central
South
West

219 (24.39 )
315 (35.08 )
313 (34.86 )
51 (5.68)

146 (26.59)
199 (36.25)
169 (30.78)
35 (6.19 )

Pre-Index Average
healthcare expenditure

1,706.41

1,487.91

Comorbidity Score (%)
0
1
2
3
4 and above
Cost sharing levels (%)
0-10%

P-Value

328 (36.53 )
570 (63.47)
898
42.35

254 (46.27)
295 (53.73)
549
28.77

<0.001b
0.3703a

0.2918b
0.0407a

446 (49.6)
263 (29.28)
113 (12.5)
40 (4.4)
36 (4.0)

236 (42.9)
164 (29.8)
88 (16.02)
38 (6.9)
23 (4.18)
<0.001a

254 (28.29)

117 (21.31)

11-20%
21-35%
36% and more
Plan Type (%)

356 (39.64)
257 (28.62)
31 (3.45)

176 (32.06)
237 (43.17)
19 (3.46)

Non-Fee-for-Service Plan
Fee-for-Service Plan

687 (76.5)
211 (23.5)

0.1458a

a. Pearson‟s Chi-square test
b. Student‟s t-test
ICS = Inhaled Corticosteroids
LABA= Long-Acting Beta-2 Agonists
LTRA= Leukotrine receptor Antagonist
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438 (79.78)
111 (20.22)

Table 8 Multivariate regression: association between cost sharing and LABA/LTRA
adherence
ICS + LABA

ICS + LTRA

Variable

Parameter
Estimate

P-Value

Parameter
Estimate

P-Value

Cost sharing

-0.00427

<.0001*

-0.005

0.0002*

Age

0.00215

<.0001*

0.00103

0.1198

Gender
Male (Reference)
Female

-0.04687

0.0127

-0.0173

0.5145

Region
South (Reference)
Northeast
North Central

-0.00808
0.03558

0.733
0.1256

0.06513
0.05034

0.0548
0.1385

West

0.10226

0.0106*

0.02431

0.6636

Pre-Index Healthcare
Expenditure

-0.00058885

0.8285

-0.00595

0.1485

Comorbidity Index

0.00333

0.6764

0.00854

0.3962

-0.09344

0.0001*

-0.06162

0.0923

Plan Type
Non-Fee-for-Service Plan
(Reference)
Fee- for-Service Plan

* Statistically significant at 0.05 alpha
ICS = Inhaled Corticosteroids
LABA= Long-Acting Beta-2 Agonists
LTRA= Leukotrine receptor Antagonist
n: 1442 R-Square: 0.35
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Table 9 Unadjusted healthcare utilization for the post-index follow up period
Description

ICS+LABA

ICS+LTRA

Patients having at least one ER
visit (%)
Patients having at least one
hospitalization (%)

84 (9.3)

50 (9.1)

37 (4.12)

30 (5.46)

Average number of SAB
prescriptions (SD)

2.12 (5.05 )

2.47( 4.31)

Adherence (SD)

0.43( 0.23)

0.48 (0.24 )

ICS = Inhaled Corticosteroids
LABA = Long-Acting Beta-2 Agonists
LTRA = Leukotrine receptor Antagonist
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A multivariate two stage regression model was built to quantify the relationship
between adherence and ER visits. Results from the regression model (Table 10) showed
an overall drop in number of ER visits with the increase in adherence levels (β = -0.634 p
= <0.05). However when analyzed the similar association within ICS+LABA and
ICS+LTRA cohorts separately, only ICS+LABA (β = -0.1244 p = 0.0075) group showed
a drop in ER visits with respect to the adherence level (Table 11). Regarding the
covariates used in this model only comorbidity index (β = -0.02011 p = <0.001) had a
significant association with the ER visits.
Another multivariate two stage regression model was built to quantify the
relationship between adherence and hospitalization. Results from the regression model
(Table 12) showed no significant relationship between controller adherence and hospital
stay (β = -0.1140 p = 0.2286). When the same relationship was analyzed separately for
ICS+LABA(β = -0.08789 p = 0.2257) and ICS+LTRA(β = 0.1768 p = 0.374), none of the
models yielded significant association between controller adherence and hospital stay
(Table 13) Among the other predictors only comorbidity score (β = -0.0408 p = 0.0045)
was found to be associated with the hospital stay.
To analyze the association between SAB use and controller adherence a similar
multivariate two stage regression model was built (Table 14). The same relationship was
analyzed separately for ICS+LABA(β = -0.0090 p = 0.9553) and ICS+LTRA(β = -0.0519
p = 0.6557), none of the models yielded significant association between controller
adherence and SAB use (Table 15) This model also did not show any significant
association between controller adherence and SAB use (β = 0.02498 p = 0.7971) and
among the other predictors only age (β = -0.02881 p =0.008) and age square (β = 0.00046
p = 0.0026) were significantly associated with the controller adherence.
The null hypotheses for all three health services utilization outcomes expected
reduction in the utilization with respect to the controller adherence. However, only in
case of ER visits reduction in utilization was observed to be significantly associated with
the reduction in utilization and therefore the null hypothesis was rejected only in case of
ER visits. In case of hospital stay and SAB use the null hypothesis could not be rejected.
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Table 10 Multivariate two stage regression: association between controller adherence and
number of ER visits
Variable

Parameter Estimate

P-Value

Adherence

-0.06341

0.05*

Age
Age Square

0.000116
-0.00002

0.9739
0.6293

-0.00213

0.9408

-0.01252
0.007575
-0.02653

0.7258
0.8265
0.6591

-0.00648

0.5745

Comorbidity Index

0.020117

<.0001*

Plan Type
Non-Fee-for-Service Plan
(Reference)
Fee- for-Service Plan

0.01314

0.7173

Gender
Male (Reference)
Female
Region
South (Reference)
Northeast
North Central
West
Pre-Index Healthcare
Expenditure

* Statistically significant at 0.05 alpha
n: 1442 R-Square: 0.42

50

Table 11 Multivariate two stage regression: association between controller adherence and
ER visits among ICS+LABA and ICS+LTRA cohorts
ICS + LABA
Variable

Parameter
Estimate

Adherence

ICS+ LTRA

P-Value

Parameter
Estimate

P-Value

-0.12448

0.0075*

-0.0198

0.6961

Age

0.00293

0.533

-0.0017

0.7919

Age Square

-0.00005245

0.4049

-0.00000444

0.964

Gender
Male (Reference)
Female

-0.00796

0.8152

0.00019083

0.997

Region
South (Reference)
Northeast
North Central
West

0.01075
0.06199
-0.02247

0.7987
0.1268
0.7542

-0.06388
-0.07464
-0.04219

0.326
0.2377
0.6935

Pre-Index Healthcare
Expenditure

0.01075

0.4528

-0.02747

0.1601

Comorbidity Index

0.0182

0.0012*

0.02337

0.0142*

-0.02303

0.5864

0.06984

0.2982

Plan Type
Non Fee-for-Service Plan
(Reference)
Fee- for-Service Plan

* Statistically significant at 0.05 alpha
ICS = Inhaled Corticosteroids
LABA= Long-Acting Beta-2 Agonists
LTRA = Leukotrine receptor Antagonist
n: 1442 R-Square: 0.44
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Table 12 Multivariate two stage regression: association between controller adherence and
number of hospital days

Variable

Parameter Estimate

P-Value

Adherence

0.114093

0.2286

Age

-0.01037

0.317

Age Square

0.000183

0.2175

0.078549

0.3493

Northeast

-0.11808

0.2579

North Central

-0.17505

0.0833

West
Pre-Index Healthcare
Expenditure

-0.07082

0.687

0.023119

0.4929

Comorbidity Index

0.040898

0.0045*

-0.0396

0.7089

Gender
Male (Reference)
Female
Region
South (Reference)

Plan Type
Non Fee-for-Service Plan
(Reference)
Fee- For-Service Plan
* Statistically significant at 0.05 alpha
n: 1442 R-Square: 0.23
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Table 13 Multivariate two stage regression: association between controller adherence and
hospital stay among ICS+LABA and ICS+LTRA cohorts
ICS + LABA
Variable

Parameter
Estimate

ICS+ LTRA

P-Value

Parameter Estimate

P-Value

Adherence

-0.08789

0.2257

0.1768

0.374

Age

-0.01012

0.1679

-0.02182

0.388

Age Square

0.00014782

0.1331

0.00045309

0.2405

Gender
Male (Reference)
Female

0.00835

0.8752

0.18954

0.3473

Region
South (Reference)
Northeast
North Central
West

0.00672
-0.03332
0.01053

0.9187
0.5991
0.9251

-0.354
-0.43851
-0.2096

0.1655
0.0772
0.6177

Pre-Index Healthcare
Expenditure

-0.01872

0.4029

0.06441

0.4008

Comorbidity Index

0.03108

0.0004*

0.05729

0.1249

Plan Type
Non Fee-for-Service
Plan (Reference)
Fee- for-Service Plan

-0.0151

0.8194

-0.12201

0.6431

* Statistically significant at 0.05 alpha
ICS = Inhaled Corticosteroids
LABA= Long-Acting Beta-2 Agonists
LTRA= Leukotrine receptor Antagonist
n: 1442 R-Square: 0.22
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Table 14 Multivariate two stage regression: association between controller adherence and
SAB refills
Variable

Parameter Estimate

P-Value

Adherence
Age
Age Square

0.024983
-0.02881
0.00046

0.7971
0.0068*
0.0026*

-0.06494

0.4507

South (Reference)
Northeast
North Central
West

-0.17179
-0.15794
-0.10106

0.1087
0.1277
0.5752

Pre-Index Healthcare
Expenditure

0.000428

0.9901

Comorbidity Index

0.006535

0.6579

Plan Type
Non-Fee-for-Service Plan
(Reference)
Fee- for-Service Plan

0.020267

0.8522

Gender
Male (Reference)
Female
Region

* Statistically significant at 0.05 alpha
n: 1442 R-Square: 0.31
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Table 15 Multivariate two stage regression: association between controller adherence and
SAB refills among ICS+LABA and ICS+LTRA cohorts
ICS + LABA

Variable

Parameter
Estimate

Adherence

ICS+ LTRA

P-Value

Parameter
Estimate

P-Value

-0.00906

0.9553

-0.05194

0.6567

Age
Age Square

-0.01974
0.00033133

0.2275
0.1313

-0.0441
0.00075351

0.0031*
0.0009

Gender
Male (Reference)
Female

-0.11824

0.3191

0.00011065

0.9993

Region
South (Reference)
Northeast
North Central
West

-0.25652
-0.10307
-0.34779

0.081
0.466
0.1644

-0.05493
-0.24709
0.27303

0.7141
0.0903
0.2689

Pre-Index Healthcare
Expenditure

-0.00884

0.6507

0.03117

0.1554

Comorbidity Index

-0.02794

0.5756

0.02121

0.6379

Plan Type
Non Fee-for-Service
plan (Reference)
Fee- for-Service Plan

-0.05342

0.7172

0.12092

0.4347

* Statistically significant at 0.05 alpha
ICS = Inhaled Corticosteroids
LABA= Long-Acting Beta-2 Agonists
LTRA = Leukotrine receptor Antagonist
n: 1442 R-Square: 0.37
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Chapter V: Discussion

Prescription drug cost sharing has been used as an effective strategy to control
prescription drug costs in both privately and publicly funded health plans. Although this
strategy has shown reduction in expenditure, the current literature has reported its
negative effects such as treatment disruption or discontinuation among chronically ill
patients.35 Additionally, higher levels of cost sharing can have considerable effects on the
use of essential or maintenance medications, and outcomes associated with care. The
literature on cost sharing clearly indicates that higher levels of cost sharing result in a
larger financial burden to the patient. Currently the majority of studies dealing with the
effects of cost sharing focus on homogeneous populations. However, different groups of
patients especially those who are chronically ill are affected differently and therefore
there is strong need to analyze effects of cost sharing levels on varied subgroups of
individuals.35 The present study aimed at determining impact of cost sharing levels on
adherence to the treatment regimen in case of asthma patients with moderate persistent
asthma.
The final sample for this study had more females than males. This has been
consistent with the existing literature on asthma drug therapy. Despite the guidelines‟
preference for ICS + LABA combination as a step up therapy, a significant percentage of
asthma patients were found to be on ICS +LTRA. This showed the fact that leukotrine
receptor modifiers still have a place in current asthma medication treatment. Other
demographics such as age and geographical region were consistent with the asthma
literature except for region west which had a very low number of study subjects.

5.1. Cost Sharing and Adherence
Results of the study showed an overall negative relationship between cost sharing
and adherence to controller drug therapy. It is clear from the results that among the study
population, as the cost sharing goes up, adherence levels start dropping significantly.
Compared to the patients that had cost sharing at 0-10% level, as the cost sharing went up
adherence dropped gradually at every increase in cost sharing. This effect is more
prominent when cost sharing levels are at maximum level. Adherence dropped by 19%
for patients that had cost sharing at 35% and above (Table1). Analysis also revealed a
negative relationship between cost sharing levels and adherence before and after they are
stepped up to dual controller therapy. When compared for the cost sensitivity to ICS
before and after, patients showed slightly higher sensitivity to ICS after getting stepped to
the dual controller therapy. According to the national guidelines patients are stepped up
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to dual controller therapy when their asthma is not controlled by ICS alone. In such
patients asthma severity level is higher and therefore there is a greater need to be
adherent to the prescribed regimen. However, as the patient has to purchase two
medications instead of one, the cost burden is greater. Patients with uncontrolled asthma
that were stepped up to the dual controller therapy had a drop in adherence in after they
were stepped up to dual controller therapy. Therefore it can be concluded that the
increased cost burden plays a significant role in case of these patients.
Comparative analysis between ICS+LABA and ICS+LTRA showed that patients
in ICS+LTRA are more sensitive to cost sharing levels than the patients using
ICS+LABA. As shown in Table 8 the drop in adherence with respect to cost sharing was
greater in case of ICS+LTRA (β = -0.005 p = 0.0002) compared to ICS+LABA (β =
0.00427 p <0.0001) subgroup. One probable reason behind that could be the difference in
mechanisms of these two add-on drugs. Both the combinations ICS/LTRA ICS/LABA‟
have demonstrated improvements in terms of asthma symptoms and exacerbation rates117;
however, both combinations achieve symptomatic relief through different mechanisms.
This difference is mainly attributed to the fact that ICS/LABA combination focuses on
improving the lung function whereas; ICS/LTRA‟s combination focuses on
complementary suppression of the airway inflammation. Because of this property LABA
are known to produce some symptomatic relief along with the controlling the condition
however LTRA does not produce any symptomatic relief along with controlling the
inflammation. It could be possible that because of this characteristic patients may value
ICS + LABA combination slightly more that the ICS+LTRA combination and therefore
they are more sensitive to cost sharing levels in case ICS+LTRA.
In general, despite the recommended guidelines on use of controller drugs, the
data showed poor adherence levels with all the controller drugs which were included in
this study. The average adherence was 0.48 for the combined controller dug therapy. This
is in agreement with the existing literature. Besides the cost sharing, type of insurance
plan was also significantly associated with the adherence to controller regimen. Patients
in non fee for service plans such as HMO and PPO had better adherence to the all
regimens while patients in fee for service plans were less adherent to the prescribed
regimen. This underlines the fact that managed care plans are doing better in terms of
adherence to the controller drugs. A study done by Crown et al.25 also found that the
patients in fee for service plan had a lower adherence to the controller drugs.
Further the study also found that geographical region was a significant predictor
of the controller drug use. Compared to all other regions, subjects from south were found
to be less adherent to the prescribed therapy. Regarding the age of patients, a curvilinear
relationship was observed. Inclusion of age and age square variables revealed that
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initially the adherence levels went up as the age was increased and after a certain age
adherence levels started dropping with the increase in age. Gender was not found to be
associated with the controller adherence. The pre-index healthcare expenditure had a
negative correlation with the controller adherence which shows that higher the economic
burden could put budget constraints leading to decreased controller adherence.

5.2 Health Services Utilization Outcomes
The study further analyzed the association of adherence and asthma related health
services utilization such as ER visits, hospital stay and use of SAB. Although health
services utilization is not a direct measure of health status or quality of care, increase in
utilization of services such as emergency room visits, hospitalization, inpatient and
outpatient visits indicate poor health outcomes. Results from this analysis indicated
mixed effects regarding the health services utilization. The number of asthma related ER
visits were found to be associated with the adherence levels. In general the patients that
had higher adherence to the controller regimen had less ER visits after controlling for
other factors. Association of higher adherence values to the lower number of ER visits
indirectly indicates the better control of asthma. However when the similar analysis was
done by separating the study population in to two groups based on the step up therapy
they received, only subjects in ICS+LABA had a statistically significant association
between the adherence and ER visits. This is also in agreement with the existing
literature, which documents better efficacy data for ICS+LABA combination than the
ICS +LTRA.
In the case of other health services utilization outcomes, contrary to the study
hypothesis, hospital stay and use of SABs were not found to be significantly associated
with the overall controller adherence levels as well the adherence levels to the individual
add-on drug. Since the total number of hospitalizations in post index was low it might be
possible that the study could not capture enough number of hospitalizations to establish a
significant association.
In case of SAB use, the controller adherence did not affect the utilization. As
controller adherence is expected to be associated with improved control over asthma it
was hypothesized that the improved control would lead to decreased symptoms and
therefore decreased use of SAB. However the analysis did not show any significant
association between controller adherence and SAB use. This can be explained by the
possibility that a sub group of patients even though adherent to the controller medication
may not be able to administer the controller drugs properly or likely to over treat the
symptoms resulting in concurrent use of SABs. In a study done by Butz et al.88 found that
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among pediatric asthma patients rate of SAB use actually went up with the use of
controller drugs. They also postulated a possibility of sub groups of asthma patients
having tendency to consume more drugs.

5.3 Policy Implications
This study could impact multiple interest groups namely insurance companies,
managed care organizations, government agencies such as Medicaid/Medicare, Health
care providers and asthma patients.
Insurance companies/ Managed care designing pharmacy benefit plan: designing
the pharmacy benefit plan in terms of various cost sharing levels is a challenging task for
insurance companies and government agencies. Since the out of pocket cost plays an
important role in the utilization of drugs89, defining the various cost sharing levels is
crucial to optimize the drug utilization and improve adherence. From the health insurance
companies‟ perspective, well-structured patient cost-sharing policies,90,91 have been
shown to be more efficient in increasing the cost savings without adversely affecting the
health outcomes.
This study will provide helpful information in designing the patient cost sharing
policies regarding the asthma controller drugs. The data such as price sensitivity of addon drugs will be helpful in determining the optimum cost sharing levels for the different
add on therapies in a pharmacy benefit management policies. The benefits discussed
above will apply to state Medicaid programs covering prescription drugs and also to
Medicare because of the part D coverage now available to the Medicare beneficiaries.
Patients‟ perspective: According to a 2002 national estimate, there are 20 million
cases of asthma in the US53 and this number is rising every year. Since asthma is a
chronic condition with no cure available and treatment relying heavily on medication
therapy, appropriate utilization of medication is imperative. Number of studies 10,
92
recently have demonstrated the reduced morbidity and improved asthma control being
associated with the appropriate drug utilization. The current literature also documents
considerable divergence10 from asthma guidelines in terms of controller drug utilization.
This study will be helpful in explaining the role played by cost sharing levels in asthma
patients‟ adherence to controller medication and different add-on options. The results
from this study will be helpful in creating awareness amongst asthma patients about
importance of controller medication for long term management of the asthma. It is
expected that the policy changes based on the study results to be directed towards
patient‟s interests to maximize the adherence to the controller treatment regimens.
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Health care provider‟s perspective: The current literature provides convincing
data on efficacy of both LABA and LTRA combinations through various clinical trials.
However, there are a few controversies87 regarding the absolute dominance of one
combination on other regarding the clinical outcomes. In terms of effectiveness of the
combinations the data available from observational studies93-95 differ in their conclusions
to establish a clear alternative. Therefore in a situation where there is no apparent
dominant strategy in terms of efficacy and effectiveness, this study will be useful in
documenting information regarding the factors such as adherence of these options and
their sensitivity to patient cost-sharing levels. The results from this study will be valuable
to physicians and other health care providers in deciding the most appropriate add-on
therapy that will improve the outcomes as well as adherence. The information such as
knowing the combination therapies to which patients are more sensitive to cost can help
understating the additional attention required in monitoring the adherence of the patients
on those combinations.

5.4 Future Research Directions
For future studies more research should be done to generate more evidence
establishing the cost sharing and adherence relationship. One possible way to improve
this study would be to add more years of data so that the study subjects could be followed
for a longer period of time this may produce more accurate estimates. Adding more years
can also increase the sample size significantly allowing using more advanced techniques
such as propensity score matching. Since there are new drugs introduced every year, the
similar approach can be used by studying more recent data that can provide most recent
drugs available in the market. Another limitation of this study was information on race
and ethnicity was not available and therefore in future studies it would be interesting to
collect information on race ethnicity that could be linked to the insurance claims data to
get more accurate and unbiased estimates. The study also did not include data on income
level and secondary insurance because of the limited information available in insurance
claims database. To overcome these limitations, in future research, it would be of great
importance to collect data on variables unavailable in insurance claims, such as race,
ethnicity, income, secondary insurance. Combining this information with administrative
claims data would create an ideal dataset to study more accurate and unbiased
relationship.
The study showed lower adherence levels both pre and post index period,
therefore future studies should investigate the role played by adherence levels in
increasing asthma severity levels that lead to stepped up therapy. Currently the asthma
treatment guidelines are based on the severity levels. If the severity levels are affected by
the adherence then more attention needs to be focused in improving the adherence
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because in such cases where patient is stepped up to dual controller therapy as result of
lower adherence to prescribed drugs, stepping up may not be an appropriate choice.
Finally, as the scope of this study was limited to patients with asthma only, this
framework can be further extended to include more chronic conditions such as
hypertension and diabetes where adherence to medication is very important in controlling
the condition. Similar approaches in investigating those factors would be helpful in
determining how price sensitive people are across a broad range of therapeutic groups
which would ultimately help in designing most appropriate drug benefit plan.
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